Sacubitril / Valsartan (Entresto) Entresto | European Medicines Agency (EMA)Skip to main contentSearchMain navigation * Medicines * Find medicine * Therapeutic areas: latest updates * Download medicine data * What we publish on medicines and when * Medicines under evaluation * National registers * Human regulatory * Overview * Research and development * Marketing authorisation * Post published: 01/12/2015Last updated: 22/06/2023Viewsvenska (SV) (69.37 KB - PDF) First published: 01/12/2015Last updated: 22/06/2023ViewProduct detailsName of medicine Entresto Active substance * sacubitril * valsartan International non-proprietary name (INN) or common name * sacubitril * valsartan Therapeutic area (MeSH) Heart Failure Anatomical therapeutic chemical (ATC) code C09DX04 Pharmacotherapeutic
Sacubitril/valsartan (heart failure, children and adolescents) ' Addendum to Commission A23-56 1 Translation of addendum Sacubitril/Valsartan (Herzinsuffizienz, Kinder und Jugendliche) – Addendum zum Projekt A23-56 (Dossierbewertung). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Sacubitril/valsartan (heart failure, children and adolescents) Addendum to Project A23-56 (dossier assessment)1 ADDENDUM Project: A23-103 Version: 1.0 Status: 9 November 2023 Addendum A23-103 Version 1.0 Sacubitril/valsartan – Addendum to Project A23-56 9 November 2023 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality
Sacubitril/valsartan (heart failure, children and adolescents) ' Benefit assessment according to '35a Social Code Book V 1 Translation of Sections I 1 to I 6 of the dossier assessment Sacubitril/Valsartan (Herzinsuffizienz, Kinder und Jugendliche) – Nutzenbewertung gemäß § 35a SGB V. Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Sacubitril/valsartan (heart failure, children and adolescents) Benefit assessment according to §35a SGB V1 EXTRACT Project: A23-56 Version: 1.1 Status: 31 October 2023 Extract of dossier assessment A23-56 Version 1.1 Sacubitril/valsartan ( heart failure, children and adolescents) 31 October 2023 Institute for Quality and Efficiency
Patient Focus: Should You Take Sacubitril/Valsartan if You Have Heart Failure With an Ejection Fraction >40% and Low Blood Pressure? An Explanation of the Association of Sacubitril/Valsartan vs Valsartan With Blood Pressure Changes and Symptomatic Hypote
Dosing patterns and dose effects of sacubitril/valsartan: A claims-based retrospective cohort study. The goals of this retrospective cohort analysis were to determine real-world dose and titration patterns of sacubitril/valsartan (SAC/VAL), a heart failure medication, and examine whether dose patterns are associated with healthcare utilization and costs. Adult health plan members (18-100 years
Combination Use of Ivabradine with Sacubitril/Valsartan: A Review of Clinical Effectiveness and Guidelines Combination Use of Ivabradine with Sacubitril/Valsartan: A Review of Clinical Effectiveness and Guidelines | CADTH Skip to main content * About * Collaboration/Outreach * Patient/Community * Careers * Contact * My CADTH * FR * Reports * Reports * Reimbursement Review with Sacubitril/Valsartan: A Review of Clinical Effectiveness and Guidelines Copied to clipboard Combination Use of Ivabradine with Sacubitril/Valsartan: A Review of Clinical Effectiveness and Guidelines ( Last Updated : February 24, 2020) Project Line: Health Technology Review Project Sub Line: Summary with Critical Appraisal Project Number: RC1247-000 DetailsQuestion 1. 2. What is the clinical effectiveness
Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure The efficacy and safety of sacubitril/valsartan in patients hospitalized with heart failure (HF) across the spectrum of left ventricular ejection fraction (EF) has not been described. Data from randomized trials of sacubitril/valsartan in HF patients with EF ≤40% (PIONEER-HF [Comparison of Sacubitril/Valsartan Versus trials of sacubitril/valsartan vs control therapy (enalapril or valsartan, respectively). All participants in the PIONEER-HF trial and 69.5% in the PARAGLIDE-HF trial were enrolled during hospitalization for HF after stabilization. The remainder in the PARAGLIDE-HF trial were enrolled ≤30 days after a WHF event. The primary endpoint of both trials was time-averaged proportional change in N-terminal pro
ENTRESTO - Sacubitril/valsartan (as sacubitrilvalsartan sodium hydrate complex) Search Page - Drug and Health Product Register * Skip to main content * Skip to "About this site"Language selection * FrançaisGovernment of CanadaSearch and menus * Search and menusSearchSearch websiteSearchTopics menu * Jobs * Immigration * Travel * Business * Benefits * Health * Taxes * More servicesYou are here
Sacubitril/valsartan versus valsartan initiation in patients naïve to renin-angiotensin system inhibitors: Insights from PARAGLIDE-HF. Whether prior treatment with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) modifies efficacy and safety of sacubitril/valsartan (Sac/Val) in patients with heart failure (HF) and ejection fraction (EF) >40% is unclear
Efficacy and Safety of Sacubitril/Valsartan Versus Amlodipine in Japanese Patients With Essential Hypertension: A Randomized, Multicenter, Open-Label, Noninferiority Study (PARASOL Study). Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has demonstrated a superior blood pressure-lowering effect compared with renin-angiotensin system inhibitors in several clinical trials . However, there has been no available evidence on the comparison between sacubitril/valsartan and calcium channel blockers (CCBs), a well-established class of antihypertensive drugs. In this open-label, multicenter study, we aimed to demonstrate the efficacy and safety of sacubitril/valsartan versus amlodipine, one of the most widely used CCBs, after 8 weeks of treatment. A total of 359 Japanese patients
Sacubitril/Valsartan partially alleviates myocardial infarction injury by activating the FGF21 signaling pathway via PPARs. The recent discovery of clinically significant data, alongside novel physiological and pathological occurrences surrounding sacubitril/valsartan (Sac/Val) beyond its approved indications, necessitates an urgent reevaluation of its underlying mechanism of action
Clinical efficacy of sacubitril/valsartan combined with cardiac rehabilitation in patients with heart failure after acute myocardial infarction: a single-center randomized trial. To investigate the effect of sacubitril/valsartan (ARNI) combined with cardiac rehabilitation (CR) in patients with heart failure (HF) after acute myocardial infarction (AMI). A total of 118 patients with HF after AMI
In-Hospital or Out-of-Hospital Initiation of Sacubitril/Valsartan Versus Valsartan in Patients With Mildly Reduced or Preserved Ejection Fraction After A Worsening Heart Failure Event: The PARAGLIDE-HF Trial. Efficacy and tolerability of sacubitril/valsartan (Sac/Val) is not well characterized in heart failure (HF) with ejection fraction >40% initiated in-hospital. Thus, this prespecified
Clinical outcomes according to the average daily dose of sacubitril/valsartan: a nationwide longitudinal cohort study. A minority of patients with heart failure (HF) are prescribed the maximal dose of the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan. We investigated the effectiveness of submaximal doses of sacubitril/valsartan in a real-world cohort. Patients with HF with reduced ejection fraction prescribed sacubitril/valsartan for ≥ 180 days between 2016 and 2020 were included from a nationwide database, and categorized into tertiles based on the average daily sacubitril/valsartan dosage. Baseline characteristics were balanced using inverse probability of treatment weighting with propensity scores. The primary outcome was a composite of HF hospitalization and all-cause
Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF The PARAGLIDE-HF trial demonstrated reductions in natriuretic peptides with sacubitril/valsartan compared with valsartan in patients with heart failure (HF) with mildly reduced or preserved ejection fraction who had a recent worsening HF event, but was not adequately powered to examine clinical outcomes. PARAGON-HF included a subset of PARAGLIDE-HF-like patients who were recently hospitalized for HF. Participant-level data from PARAGLIDE-HF and PARAGON-HF were pooled to better estimate the efficacy and safety of sacubitril/valsartan in reducing cardiovascular and renal events in HF with mildly reduced or preserved ejection
Effect of sacubitril/valsartan on brain natriuretic peptide level and prognosis of acute cerebral infarction. Previous studies demonstrated that elevated brain natriuretic peptide (BNP) level is associated with adverse clinical outcomes of acute cerebral infarction (ACI). Researchers hypothesized that BNP might be a potential neuroprotective factor against cerebral ischemia because of the antagonistic effect of the natriuretic peptide system on the renin-angiotensin system and regulation of cardiovascular homeostasis. However, whether decreasing the BNP level can improve the prognosis of ACI has not been studied yet. The main effect of sacubitril/valsartan is to enhance the natriuretic peptide system. We investigated whether the intervention of plasma BNP levels with sacubitril/valsartan
Comparative Risk of Angioedema With Sacubitril-Valsartan vs Renin-Angiotensin-Aldosterone Inhibitors Data on angioedema risk among sacubitril-valsartan (SV) users in real-world settings are limited. We sought to evaluate the risk of angioedema among SV new users compared with angiotensin-converting enzyme (ACE) inhibitor and angiotensin-receptor-blocker (ARB) new users separately. We conducted
Antiarrhythmic and Anti-Inflammatory Effects of Sacubitril/Valsartan on Post-Myocardial Infarction Scar. Sacubitril/valsartan (Sac/Val) is superior to angiotensin-converting enzyme inhibitors in reducing the risk of heart failure hospitalization and cardiovascular death, but its mechanistic data on myocardial scar after myocardial infarction (MI) are lacking. The objective of this work
Efficacy of Sacubitril-Valsartan on Survival and Cardiac Remodeling in Hypotensive Heart Failure With Reduced Ejection Fraction: A Multicenter Study. To investigate whether hypotensive patients diagnosed with heart failure and reduced ejection fraction (HFrEF) might benefit from angiotensin receptor-neprilysin inhibitors (ARNis) in real-world practice because patients with baseline systolic
Effects of sacubitril/valsartan according to polypharmacy status in PARAGON-HF. Patients with heart failure (HF) and preserved ejection fraction (HFpEF) have a particularly high prevalence of comorbidities, often necessitating treatment with many medications. The aim of this study was to evaluate the association between polypharmacy status and outcomes in PARAGON-HF. In this post hoc analysis , baseline medication status was available in 4793 of 4796 patients included in the primary analysis of PARAGON-HF. The effects of sacubitril/valsartan, compared with valsartan, were assessed according to the number of medications at baseline: 683 non-polypharmacy (<5 medications); 2750 polypharmacy (5-9 medications), and 1360 hyper-polypharmacy (≥10 medications). The primary outcome was total HF